



Clinical trial results:

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis

Summary

EudraCT number	2017-002988-18
Trial protocol	DE AT DK HU FR SE EE ES NL PT SI BE HR GB NO FI IT
Global end of trial date	24 November 2020

Results information

Result version number	v1 (current)
This version publication date	05 December 2021
First version publication date	05 December 2021

Trial information

Trial identification

Sponsor protocol code	EFC15068
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03600805
WHO universal trial number (UTN)	U1111-1200-2184

Notes:

Sponsors

Sponsor organisation name	Sanofi-aventis Recherche & Développement
Sponsor organisation address	1 avenue Pierre Brossolette, Chilly Mazarin Cedex, France, 91385
Public contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 February 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	24 November 2020
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of sarilumab in subjects with giant cell arteritis (GCA) as assessed by the proportion of subjects with sustained remission at Week 52 for sarilumab compared to placebo, in combination with a 26-week corticosteroid (CS) tapering course.

Protection of trial subjects:

Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 November 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	Sweden: 1
Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	Switzerland: 3
Country: Number of subjects enrolled	Spain: 11
Country: Number of subjects enrolled	Russian Federation: 2
Country: Number of subjects enrolled	Argentina: 2
Country: Number of subjects enrolled	Israel: 2
Country: Number of subjects enrolled	Italy: 6
Country: Number of subjects enrolled	Germany: 11
Country: Number of subjects enrolled	United Kingdom: 6
Country: Number of subjects enrolled	Portugal: 2
Country: Number of subjects enrolled	Croatia: 1
Country: Number of subjects enrolled	Denmark: 8
Country: Number of subjects enrolled	France: 10
Country: Number of subjects enrolled	Slovenia: 1

Country: Number of subjects enrolled	United States: 6
Country: Number of subjects enrolled	Australia: 2
Worldwide total number of subjects	83
EEA total number of subjects	56

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	18
From 65 to 84 years	61
85 years and over	4

Subject disposition

Recruitment

Recruitment details:

Study was conducted at 48 active centers in 19 countries. A total of 125 subjects were screened between 20 November 2018 and 19 March 2020, of whom 42 subjects were screen failures. Screen failures were mainly due to not meeting inclusion criteria. A total of 83 subjects were enrolled and randomised in the study.

Pre-assignment

Screening details:

Subjects were randomised to 4 treatments arms in 2:1:1:2 ratio by interactive response technology stratified by starting dose of prednisone at Baseline (less than [$<$] 30 milligrams per day (mg/day) or greater than or equal to [\geq] 30 mg/day).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo+52 week taper

Arm description:

Subjects received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.

Arm type	Placebo
Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Prednisone or Prednisone matched to placebo tapering oral doses daily for 26 weeks according to the protocol-defined schedule.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo matched to sarilumab, single SC injection q2w for 52 weeks.

Arm title	Placebo+26 week taper
------------------	-----------------------

Arm description:

Subjects received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo matched to sarilumab, single SC injection q2w for 52 weeks.

Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Prednisone or Prednisone matched to placebo tapering oral doses daily for 26 weeks according to the protocol-defined schedule.

Arm title	Sarilumab 150mg q2w+26 week taper
------------------	-----------------------------------

Arm description:

Subjects received sarilumab 150 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Arm type	Experimental
Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Prednisone or Prednisone matched to placebo tapering oral doses daily for 26 weeks according to the protocol-defined schedule.

Investigational medicinal product name	Sarilumab (150 mg)
Investigational medicinal product code	SAR153191
Other name	Kevzara®
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Sarilumab 150 mg, single SC injection q2w for 52 weeks.

Arm title	Sarilumab 200mg q2w+26 week taper
------------------	-----------------------------------

Arm description:

Subjects received sarilumab 200 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Arm type	Experimental
Investigational medicinal product name	Prednisone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Prednisone or Prednisone matched to placebo tapering oral doses daily for 26 weeks according to the protocol-defined schedule.

Investigational medicinal product name	Sarilumab (200 mg)
Investigational medicinal product code	SAR153191
Other name	Kevzara®
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Sarilumab 200 mg, single SC injection q2w for 52 weeks.

Number of subjects in period 1	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper
Started	28	14	14
Week 52 Analysis set Population	10	6	7
Completed	9	6	6
Not completed	19	8	8
Consent withdrawn by subject	1	-	-
Other unspecified	14	6	7
Adverse event, non-fatal	2	1	1
Lack of efficacy	2	1	-

Number of subjects in period 1	Sarilumab 200mg q2w+26 week taper
Started	27
Week 52 Analysis set Population	13
Completed	8
Not completed	19
Consent withdrawn by subject	1
Other unspecified	11
Adverse event, non-fatal	7
Lack of efficacy	-

Baseline characteristics

Reporting groups

Reporting group title	Placebo+52 week taper
Reporting group description: Subjects received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.	
Reporting group title	Placebo+26 week taper
Reporting group description: Subjects received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	
Reporting group title	Sarilumab 150mg q2w+26 week taper
Reporting group description: Subjects received sarilumab 150 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	
Reporting group title	Sarilumab 200mg q2w+26 week taper
Reporting group description: Subjects received sarilumab 200 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	

Reporting group values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper
Number of subjects	28	14	14
Age categorical Units: Subjects			

Age continuous Units: years arithmetic mean standard deviation	71.4 ± 7.7	69.5 ± 5.4	67.1 ± 7.9
Gender categorical Units: Subjects			
Female	22	9	13
Male	6	5	1
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	1
White	23	13	11
More than one race	0	0	0
Unknown or Not Reported	5	1	2

Reporting group values	Sarilumab 200mg q2w+26 week taper	Total	
Number of subjects	27	83	
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	73.4 ± 8.6	-	
Gender categorical Units: Subjects			
Female	23	67	
Male	4	16	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	0	0	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	0	1	
White	25	72	
More than one race	0	0	
Unknown or Not Reported	2	10	

End points

End points reporting groups

Reporting group title	Placebo+52 week taper
Reporting group description: Subjects received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.	
Reporting group title	Placebo+26 week taper
Reporting group description: Subjects received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	
Reporting group title	Sarilumab 150mg q2w+26 week taper
Reporting group description: Subjects received sarilumab 150 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	
Reporting group title	Sarilumab 200mg q2w+26 week taper
Reporting group description: Subjects received sarilumab 200 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.	

Primary: Percentage of Subjects who Achieved Sustained Disease Remission at Week 52

End point title	Percentage of Subjects who Achieved Sustained Disease Remission at Week 52 ^[1]
End point description: Disease remission was defined as resolution of signs and symptoms of giant cell arteritis (GCA), and normalisation of C-reactive protein (CRP) (<10 mg/L). Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in corticosteroid [CS] dose due to GCA or elevation of erythrocyte sedimentation rate [ESR] attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 52, normalisation of CRP (to <10 mg/L, with absence of successive elevations to ≥10 mg/L) from Week 12 through Week 52, and successful adherence to prednisone taper from Week 12 through Week 52. Analysis was performed on Week 52 Analysis set population that included all randomised subjects who had opportunity to complete the 52-week treatment period (randomised prior to October 16th, 2019).	
End point type	Primary
End point timeframe: At Week 52	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint was descriptive in nature, no statistical analysis was provided.

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	7	13
Units: percentage of subjects				
number (not applicable)	30.0	0	42.9	46.2

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Subjects who Achieved Sustained Disease Remission at Week 24

End point title	Percentage of Subjects who Achieved Sustained Disease Remission at Week 24 ^[2]
-----------------	---

End point description:

Disease remission was defined as resolution of signs and symptoms of GCA, and normalisation of CRP <10 mg/L. Sustained remission was defined as meeting all of the following parameters: achievement of disease remission not later than Week 12, absence of disease flare (defined as recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA) from Week 12 through Week 24, normalisation of CRP (to <10 mg/L, with an absence of successive elevations to ≥ 10 mg/L) from Week 12 through Week 24, and successful adherence to the prednisone taper from Week 12 through Week 24. Analysis was performed on intent-to-treat (ITT) population that included subjects who were allocated to a randomised treatment regardless of whether the treatment kit was used, and were analysed according to the treatment group allocated by randomisation.

End point type	Primary
----------------	---------

End point timeframe:

At Week 24

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint was descriptive in nature, no statistical analysis was provided.

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: percentage of subjects				
number (not applicable)	39.3	7.1	42.9	48.1

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Achievement of Disease Remission up to Week 12: Week 52 Analysis set

End point title	Number of Subjects With Achievement of Disease Remission up
-----------------	---

End point description:

Disease remission was defined as resolution of signs and symptoms of GCA, and normalisation of CRP (< 10 mg/L). The status of normalisation of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalisation of CRP. Subjects who took rescue corticosteroid (CS) due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12. Analysis was performed on Week 52 Analysis set.

End point type	Secondary
----------------	-----------

End point timeframe:

up to Week 12

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	7	13
Units: subjects	7	3	4	7

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Achievement of Disease Remission up to Week 12: ITT Population

End point title	Number of Subjects With Achievement of Disease Remission up to Week 12: ITT Population
-----------------	--

End point description:

Disease remission was defined as resolution of signs and symptoms of GCA, and normalisation of CRP (< 10 mg/L). The status of normalisation of CRP (<10 mg/L) was determined based on the last two non-missing post-baseline CRP values measured up to Week 12. If at least one of the value was <10 mg/L, then it was considered as normalisation of CRP. Subjects who took rescue CS due to active GCA prior to Week 12 or who permanently withdrew from the study treatment prior to Week 12 were considered as not achieved disease remission by Week 12. Analysis was performed on ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

up to Week 12

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: subjects	16	6	9	15

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Absence of Disease Flare From Week 12 Through Week 52: Week 52 Analysis set

End point title	Number of Subjects With Absence of Disease Flare From Week 12 Through Week 52: Week 52 Analysis set
-----------------	---

End point description:

Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of subjects with absence of disease flare from Week 12 through Week 52 were reported. Analysis was performed on Week 52 Analysis set.

End point type	Secondary
----------------	-----------

End point timeframe:

From Week 12 through Week 52

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	7	13
Units: subjects	7	3	4	7

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Absence of Disease Flare From Week 12 Through Week 24: ITT Population

End point title	Number of Subjects With Absence of Disease Flare From Week 12 Through Week 24: ITT Population
-----------------	---

End point description:

Disease flare was defined as either recurrence of signs and symptoms attributable to active GCA plus an increase in CS dose due to GCA, or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Number of subjects with absence of disease flare from Week 12 through Week 24 were reported. Analysis was performed on ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From Week 12 through Week 24

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: subjects	21	7	10	15

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Normalisation of C-Reactive Protein (CRP) From Week 12 Through Week 52: Week 52 Analysis set

End point title	Number of Subjects With Normalisation of C-Reactive Protein (CRP) From Week 12 Through Week 52: Week 52 Analysis set
End point description:	Normalisation of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP ≥10 mg/L, then it was categorised as no normalisation of CRP. Analysis was performed on Week 52 Analysis set.
End point type	Secondary
End point timeframe:	From Week 12 through Week 52

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	7	13
Units: subjects	6	3	5	8

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Normalisation of C-Reactive Protein From Week 12 Through Week 24: ITT Population

End point title	Number of Subjects With Normalisation of C-Reactive Protein From Week 12 Through Week 24: ITT Population
End point description:	Normalisation of CRP was defined as CRP levels <10 mg/L. If there were two or more consecutive visits with CRP ≥10 mg/L, then it was categorised as no normalisation of CRP. Analysis was performed on ITT population.

End point type	Secondary
End point timeframe:	
From Week 12 through Week 24	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: subjects	20	4	11	17

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52: Week 52 Analysis set

End point title	Number of Subjects With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52: Week 52 Analysis set
-----------------	---

End point description:

Successful adherence to the prednisone taper from Week 12 through Week 52 was defined as subjects who did not take rescue therapy from Week 12 through Week 52 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of ≤ 100 mg (or equivalent), such as those employed to manage adverse event (AE) not related to GCA. Analysis was performed on Week 52 Analysis set.

End point type	Secondary
End point timeframe:	
From Week 12 through Week 52	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	7	13
Units: subjects	6	2	3	6

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Successful Adherence to the Prednisone Taper From Week 12 Through Week 24: ITT Population

End point title	Number of Subjects With Successful Adherence to the Prednisone Taper From Week 12 Through Week 24: ITT Population
End point description: Successful adherence to the prednisone taper from Week 12 through Week 24 was defined as subjects who did not take rescue therapy from Week 12 through Week 24 and might include the use of any excess prednisone (beyond the per protocol CS tapering regimen) with a cumulative dose of ≤ 100 mg (or equivalent), such as those employed to manage AE not related to GCA. Analysis was performed on ITT population.	
End point type	Secondary
End point timeframe: From Week 12 through Week 24	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: subjects	18	5	7	13

Statistical analyses

No statistical analyses for this end point

Secondary: Total Cumulative Corticosteroid (Including Prednisone) Dose

End point title	Total Cumulative Corticosteroid (Including Prednisone) Dose
End point description: Cumulative dose of CS used for GCA disease was defined as the dose taken up to the end of treatment, including expected prednisone in tapering regimen per protocol, CS used in rescue therapy and the use of commercial prednisone (an excess of ≤ 100 mg of prednisone during the study treatment period employed to manage AE not related to GCA). The total cumulative CS dose was based on the total number of days with complete or partial intake, no imputation was done on missed tablets. Analysis was performed on ITT population.	
End point type	Secondary
End point timeframe: Up to Week 52	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: milligrams				
arithmetic mean (standard deviation)	2577.3 (\pm 1018.3)	2270.7 (\pm 1418.0)	2177.1 (\pm 1326.7)	1643.1 (\pm 967.3)

Statistical analyses

No statistical analyses for this end point

Secondary: Time to First Giant Cell Arteritis Disease Flare

End point title	Time to First Giant Cell Arteritis Disease Flare
-----------------	--

End point description:

Time to first GCA flare was defined as the duration (in days) from randomisation to first GCA flare after clinical remission (defined as resolution of signs and symptoms and normalisation of CRP [<10 mg/L]) and up to 52 weeks. Disease flare was defined as either the recurrence of signs or symptoms attributable to active plus an increase in CS dose due to GCA or elevation of ESR attributable to active GCA plus an increase in CS dose due to GCA. Kaplan-Meier method was used for the analysis. Subjects who never achieved remission were censored at randomisation day; and those who achieved clinical remission and never flared were censored at the end of treatment assessment date up to Week 52. Analysis was performed on ITT population. Here, 99999 is used as a space filler which represents that the specified field data were not estimable due to very low number of subjects with the events.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 52

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: days				
median (confidence interval 95%)	99999 (141.000 to 99999)	170.00 (85.000 to 99999)	99999 (58.000 to 99999)	99999 (77.000 to 99999)

Statistical analyses

No statistical analyses for this end point

Secondary: Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 24: ITT Population

End point title	Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 24: ITT Population
-----------------	--

End point description:

GTI assessed glucocorticoid (GC) related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was sum of 9 domain-specific scores at each visit and Cumulative GTI score was the sum of composite GTI

scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 24 are reported in this endpoint. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, the minimum score implies least toxicity and maximum score implies the most toxicity. Analysis was performed on ITT population.

End point type	Secondary
End point timeframe:	
At Week 24	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: units on a scale				
arithmetic mean (standard deviation)				
Cumulative worsening score	29.2 (± 30.8)	30.7 (± 33.2)	55.1 (± 43.1)	31.0 (± 42.9)
Aggregate improvement score	-21.6 (± 54.8)	-13.4 (± 44.3)	14.2 (± 55.0)	-3.3 (± 43.4)

Statistical analyses

No statistical analyses for this end point

Secondary: Composite Glucocorticoid Toxicity Index: Cumulative Worsening Score and Aggregate Improvement Score at Week 52

End point title	Composite Glucocorticoid Toxicity Index: Cumulative Worsening Score and Aggregate Improvement Score at Week 52
-----------------	--

End point description:

GTI assessed GC related morbidity and GC-sparing ability of other therapies; composed of 2 components: Composite GTI and Specific List. Composite GTI contained 9 domains and Specific List contained of 23 items (11 domains), used as complementary tool to C-GTI. Composite GTI score was sum of 9 domain-specific scores at each visit and Cumulative GTI score was sum of composite GTI scores across each visit. Two cumulative GTI scores: CWS and AIS at Week 52 are reported in this endpoint. CWS assessed cumulative GC toxicity regardless of whether toxicity had lasting effects or was transient. AIS assessed new therapy effectiveness in decreasing any Baseline GC toxicity over time. For CWS, composite score ranged from 0 to 439 and for AIS, composite score ranged from -346 to 439. For both CWS and AIS, minimum score implies the least toxicity and maximum score implies the most toxicity. Analysed on Week 52 analysis set. Here, 'number of subjects analysed'=subjects evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
At Week 52	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	6	6	11
Units: units on a scale				
arithmetic mean (standard deviation)				
Cumulative worsening score	73.0 (± 50.3)	84.7 (± 33.4)	77.2 (± 41.7)	52.8 (± 39.0)
Aggregate improvement score	-19.5 (± 65.0)	31.2 (± 54.7)	23.7 (± 31.9)	-0.5 (± 51.5)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

End point title	Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
-----------------	--

End point description:

An adverse event (AE) was defined as any untoward medical occurrence in a subject who received study drug and did not necessarily had to have a causal relationship with the treatment. Serious AEs (SAEs) were any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalisation, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the IMP to the last dose of the SC IMP +60 days). Analysis was performed on safety population that included subjects who had received at least one dose or part of a dose of investigational medicinal product (IMP) and were analysed according to the treatment actually received.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose (i.e., Day 1) up to 60 days after last dose (i.e., up to Week 60)

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: subjects				
Any TEAE	24	14	13	22
Any treatment emergent SAE	2	3	2	7

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK): Serum Trough Concentration (C_{trough}) of Sarilumab

End point title	Pharmacokinetics (PK): Serum Trough Concentration (C _{trough}) of Sarilumab ^[3]
-----------------	--

End point description:

C_{trough} was pre dose concentration of drug. Data for this endpoint was not planned to be collected and analysed for placebo arms (Placebo+52 Week Taper and Placebo+26 Week Taper) as pre-specified in the protocol. Analysis was performed on PK analysis population which included subjects who had received at least one dose or part of a dose of IMP, were analysed according to the treatment actually received and had at least 1 post-dose non-missing serum sarilumab concentration value. Here, 'n' = subjects with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose on Week 0 (Baseline), Weeks 2, 4, 12, 16, 24 and 52

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reported for all applicable arms in the study.

End point values	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	26		
Units: nanograms per millilitre				
arithmetic mean (standard deviation)				
Baseline (n = 14, 26)	0.00 (± 0.00)	0.00 (± 0.00)		
Week 2 (n = 14, 25)	2099.29 (± 3114.92)	5400.82 (± 4124.63)		
Week 4 (n = 13, 25)	4644.71 (± 5994.17)	11640.98 (± 8574.00)		
Week 12 (n = 13, 20)	8371.33 (± 7608.42)	27586.00 (± 17496.07)		
Week 16 (n = 12, 17)	8111.08 (± 5962.56)	28911.88 (± 20821.06)		
Week 24 (n = 12, 19)	12926.67 (± 9509.92)	35451.74 (± 23953.29)		
Week 52 (n = 6, 9)	19780.00 (± 21829.95)	46766.67 (± 21172.15)		

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24

End point title	Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24 ^[4]
-----------------	---

End point description:

Serum concentrations of functional sarilumab were analysed using validated enzyme linked immunosorbent assay. Analysis was performed on PK analysis population. Here, 'number of subjects analysed' = subjects for this endpoint. Data for this endpoint was not planned to be collected and analysed for placebo arms (Placebo+52 Week Taper and Placebo+26 Week Taper) as pre-specified in the protocol.

End point type	Secondary
----------------	-----------

End point timeframe:
post-dose at Week 24

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is reported for all applicable arms in the study.

End point values	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	13		
Units: nanograms per millilitre				
arithmetic mean (standard deviation)	25255.45 (± 17510.38)	44551.54 (± 28298.62)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Treatment-emergent Antidrug Antibodies (ADA) Response

End point title	Percentage of Subjects With Treatment-emergent Antidrug Antibodies (ADA) Response
-----------------	---

End point description:

ADA response categories: 1) Treatment-boosted ADA positive subject: subject with a positive ADA assay response at Baseline and with at least a 4-fold increase in titer compared to Baseline during TEAE period. 2) Treatment-emergent ADA positive subject: subject with non-positive assay (meaning negative or missing) response at Baseline but with a positive assay response during the TEAE period (defined as the time from the first dose of the IMP to the last dose of the SC IMP + 60 days). Titer values were categorised as low (titer <1,000); moderate (1,000 ≤ titer ≤ 10,000) and high (titer >10,000). Analysis was performed on ADA population that included subjects who had received at least one dose or part of a dose of IMP, were analysed according to the treatment actually received and had at least 1 non-missing ADA result in the ADA assay following the first dose of IMP.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 (Baseline) up to last dose date of study drug + 60 days (i.e., up to Week 60)

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	26	13	14	24
Units: percentage of subjects				
number (not applicable)				
Treatment-boosted ADA positive subjects	0	0	0	0
Treatment-emergent ADA positive subjects	3.8	0	7.1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacodynamics: Change from Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52

End point title	Pharmacodynamics: Change from Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
-----------------	---

End point description:

ESR is a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimetres per hour. Analysis was performed on ITT population. Here, 'n' = subjects with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27	11	14	24
Units: millimeters per hour				
arithmetic mean (standard deviation)				
Week 2 (n = 27, 11, 14, 24)	-1.1 (± 17.9)	0.7 (± 11.4)	-10.4 (± 16.4)	-8.8 (± 12.4)
Week 4 (n = 25, 10, 13, 25)	-4.2 (± 21.4)	5.2 (± 19.7)	-13.3 (± 22.6)	-9.4 (± 15.2)
Week 8 (n = 24, 13, 12, 24)	-2.0 (± 22.7)	10.2 (± 12.6)	-11.9 (± 18.9)	-8.7 (± 16.1)
Week 12 (n = 21, 13, 12, 23)	-1.5 (± 24.9)	9.8 (± 13.3)	-14.7 (± 19.2)	-11.0 (± 14.1)
Week 16 (n = 22, 12, 13, 19)	-4.1 (± 22.7)	9.8 (± 16.5)	-13.5 (± 18.1)	-10.4 (± 12.7)
Week 20 (n = 21, 11, 14, 20)	-6.6 (± 23.7)	8.8 (± 14.6)	-18.2 (± 23.5)	-10.9 (± 12.2)
Week 24 (n = 21, 10, 14, 22)	-4.2 (± 22.0)	13.9 (± 16.1)	-16.4 (± 25.6)	-9.3 (± 11.5)
Week 32 (n = 22, 10, 9, 17)	-7.0 (± 21.3)	6.6 (± 16.2)	-9.4 (± 18.0)	-7.9 (± 10.6)
Week 40 (n = 19, 8, 8, 14)	-1.5 (± 22.3)	4.0 (± 18.1)	-10.1 (± 25.2)	-7.9 (± 8.6)
Week 52 (n = 13, 7, 6, 10)	-1.0 (± 27.0)	-1.4 (± 12.4)	-15.2 (± 19.0)	-7.0 (± 12.0)

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacodynamics: Change from Baseline in C-reactive Protein (CRP) Level at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52

End point title	Pharmacodynamics: Change from Baseline in C-reactive Protein (CRP) Level at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52
End point description: CRP is a protein made by the liver. CRP levels increase in blood when inflammation occurs in the body. Analysis was performed on ITT population. Here, 'n' = subjects with available data for each specified category.	
End point type	Secondary
End point timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	27	11	14	26
Units: milligrams per Litre				
arithmetic mean (standard deviation)				
Week 2 (n = 27, 11, 14, 26)	0.8 (± 20.7)	-1.0 (± 21.2)	-3.5 (± 11.2)	-2.0 (± 7.6)
Week 4 (n = 25, 11, 13, 25)	-3.6 (± 19.3)	-2.2 (± 21.8)	-2.6 (± 18.7)	-1.9 (± 8.3)
Week 8 (n = 24, 13, 12, 24)	-3.8 (± 19.1)	-1.9 (± 16.6)	-3.5 (± 11.7)	-1.4 (± 5.2)
Week 12 (n = 21, 13, 13, 23)	-4.4 (± 22.0)	2.9 (± 18.9)	-3.3 (± 17.9)	-1.0 (± 8.0)
Week 16 (n = 22, 12, 13, 18)	-4.5 (± 20.7)	3.6 (± 23.3)	-5.0 (± 14.1)	-1.7 (± 2.9)
Week 20 (n = 21, 11, 14, 20)	-4.5 (± 21.1)	1.4 (± 16.4)	-7.2 (± 15.6)	-1.9 (± 3.5)
Week 24 (n = 21, 10, 13, 22)	-4.1 (± 19.5)	0.9 (± 26.9)	-5.7 (± 19.8)	-0.8 (± 4.1)
Week 32 (n = 22, 10, 9, 17)	-5.0 (± 19.2)	0.3 (± 29.1)	-6.9 (± 16.0)	-0.1 (± 5.9)
Week 40 (n = 19, 7, 8, 14)	-3.6 (± 21.1)	-8.2 (± 24.8)	-2.0 (± 10.3)	-2.0 (± 3.4)
Week 52 (n = 12, 7, 6, 10)	-1.1 (± 31.5)	-8.0 (± 27.2)	-4.8 (± 4.2)	-1.9 (± 4.6)

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacodynamics: Change from Baseline in Interleukin-6 (IL-6) Level at Weeks 2, 12, 24, and 52

End point title	Pharmacodynamics: Change from Baseline in Interleukin-6 (IL-6) Level at Weeks 2, 12, 24, and 52
End point description: Interleukin-6 is a protein produced in the body. Levels of IL-6 increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic. Analysis was performed on safety population. Here, 'n' = subjects with available data for each specified category.	
End point type	Secondary
End point timeframe: Baseline, Weeks 2, 12, 24, and 52	

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: nanograms per Litre				
arithmetic mean (standard deviation)				
Week 2 (n = 23, 8, 13, 22)	2.90 (± 17.46)	3.47 (± 10.30)	31.74 (± 31.13)	117.33 (± 245.28)
Week 12 (n = 18, 7, 11, 17)	-0.88 (± 12.60)	5.56 (± 8.08)	52.38 (± 47.46)	81.82 (± 50.85)
Week 24 (n = 20, 4, 11, 15)	-1.03 (± 7.15)	5.57 (± 19.81)	53.60 (± 53.71)	69.20 (± 46.89)
Week 52 (n = 7, 3, 3, 6)	0.43 (± 5.58)	2.82 (± 1.90)	42.14 (± 8.52)	33.28 (± 32.37)

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacodynamics: Change From Baseline in Soluble Interleukin-6 Receptor (sIL-6R) Level at Weeks 2, 12, 24, and 52

End point title	Pharmacodynamics: Change From Baseline in Soluble Interleukin-6 Receptor (sIL-6R) Level at Weeks 2, 12, 24, and 52
-----------------	--

End point description:

Interleukin-6 is a protein produced in the body. Levels of IL-6 increase when there is inflammation (redness, warmth, swelling, and pain as a result of infection, irritation, or injury), either acute or chronic. sIL-6R is one of the receptors that bind IL-6. Analysis was performed on safety population. Here, 'n' = subjects with available data for each specified category, '9999' = a space filler, which signifies that no subjects were available for assessments at the specified time points in the respective arm and '999' = a space filler, which signifies that SD was not estimable at the specified time point (i.e., sIL-6R: Week 12) because only 1 subject was available for the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 12, 24, and 52

End point values	Placebo+52 week taper	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Sarilumab 200mg q2w+26 week taper
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	14	27
Units: nanograms per millilitre				
arithmetic mean (standard deviation)				
Week 2 (n = 0, 0 13, 26)	9999 (± 9999)	9999 (± 9999)	212.19 (± 51.99)	224.87 (± 107.43)
Week 12 (n = 1, 0, 12, 21)	17.67 (± 999)	9999 (± 9999)	336.30 (± 107.49)	427.40 (± 124.97)
Week 24 (n = 3, 0, 11, 18)	-12.72 (± 3.97)	9999 (± 9999)	311.88 (± 184.32)	456.09 (± 118.07)

Week 52 (n = 8, 2, 4, 7)	-131.47 (± 356.65)	-9.69 (± 11.14)	377.23 (± 84.99)	471.16 (± 182.72)
--------------------------	-----------------------	--------------------	---------------------	----------------------

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose (i.e., Day 1) of study drug to last dose date of study drug + 60 days (i.e., up to Week 60)

Adverse event reporting additional description:

Reported AEs and deaths were treatment emergent AEs that developed/worsened in grade or became serious during TEAE period (defined as the time from the first dose of the IMP to the last dose of the SC IMP + 60 days). Analysis was performed on safety population.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

Reporting groups

Reporting group title	Placebo+26 week taper
-----------------------	-----------------------

Reporting group description:

Subjects received sarilumab-matching placebo as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Reporting group title	Sarilumab 150mg q2w+26 week taper
-----------------------	-----------------------------------

Reporting group description:

Subjects received sarilumab 150 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Reporting group title	Placebo+52 week taper
-----------------------	-----------------------

Reporting group description:

Subjects received sarilumab-matching placebo as subcutaneous (SC) injection every 2 weeks (q2w) up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone/prednisone-matching placebo tapering oral daily doses for 52 weeks.

Reporting group title	Sarilumab 200mg q2w+26 week taper
-----------------------	-----------------------------------

Reporting group description:

Subjects received sarilumab 200 mg as SC injection q2w up to 52 weeks along with the combination of prednisone and/or prednisone-matching placebo according to the protocol-defined schedule. Subjects received prednisone tapering oral daily doses during the first 26 weeks and prednisone-matching placebo from Week 26 up to Week 52.

Serious adverse events	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Placebo+52 week taper
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 14 (21.43%)	2 / 14 (14.29%)	2 / 28 (7.14%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Femur Fracture			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic Dissection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep Vein Thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	1 / 28 (3.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral Vascular Disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral Amyloid Angiopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Blindness Unilateral			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal Artery Occlusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis Ulcerative			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	1 / 28 (3.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus Hernia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute Respiratory Failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Infections and infestations			
Covid-19			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower Respiratory Tract Infection alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	1 / 28 (3.57%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic Shock alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Sarilumab 200mg q2w+26 week taper		
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 27 (25.93%)		
number of deaths (all causes)	2		
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Femur Fracture alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Aortic Dissection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Deep Vein Thrombosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral Vascular Disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebral Amyloid Angiopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Neutropenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Blindness Unilateral			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal Artery Occlusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis Ulcerative			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hiatus Hernia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute Respiratory Failure			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Covid-19			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cellulitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Lower Respiratory Tract Infection alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Septic Shock alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo+26 week taper	Sarilumab 150mg q2w+26 week taper	Placebo+52 week taper
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 14 (92.86%)	13 / 14 (92.86%)	22 / 28 (78.57%)
Vascular disorders			
Hypertension alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 14 (7.14%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	1	1	0
Hypertensive Emergency alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	2	0
Peripheral Arterial Occlusive Disease alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Phlebitis alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Fatigue alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	1	0	2
Injection Site Erythema alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	9	0
Injection Site Pain alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Injection Site Pruritus alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Injection Site Rash alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Injection Site Reaction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	4 / 14 (28.57%)	0 / 28 (0.00%)
occurrences (all)	0	8	0
Injection Site Swelling			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Malaise			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	1 / 28 (3.57%)
occurrences (all)	1	0	1
Oedema Peripheral			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Vessel Puncture Site Phlebitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Uterine Polyp			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Allergic Cough			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Cough			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	3 / 28 (10.71%)
occurrences (all)	0	0	3
Dyspnoea			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	1	1	0
Dyspnoea Exertional			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Emphysema			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Oropharyngeal Pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	2 / 14 (14.29%)	0 / 28 (0.00%)
occurrences (all)	1	3	0
Sleep Apnoea Syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Depressed Mood			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 14 (14.29%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	3	0	0
Depression			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	5 / 28 (17.86%)
occurrences (all)	1	0	5
Insomnia			
alternative dictionary used: MedDRA 23.1			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Mania</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 14 (14.29%)</p> <p>2</p> <p>5 / 14 (35.71%)</p> <p>5</p>	<p>2 / 14 (14.29%)</p> <p>2</p> <p>1 / 14 (7.14%)</p> <p>1</p>	<p>3 / 28 (10.71%)</p> <p>3</p> <p>2 / 28 (7.14%)</p> <p>2</p>
<p>Investigations</p> <p>Creatinine Renal Clearance Decreased</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>International Normalised Ratio Increased</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight Increased</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 14 (7.14%)</p> <p>1</p> <p>1 / 14 (7.14%)</p> <p>1</p> <p>0 / 14 (0.00%)</p> <p>0</p>	<p>0 / 14 (0.00%)</p> <p>0</p> <p>0 / 14 (0.00%)</p> <p>0</p> <p>0 / 14 (0.00%)</p> <p>0</p>	<p>0 / 28 (0.00%)</p> <p>0</p> <p>0 / 28 (0.00%)</p> <p>0</p> <p>0 / 28 (0.00%)</p> <p>0</p>
<p>Injury, poisoning and procedural complications</p> <p>Arthropod Bite</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Contusion</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Fall</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Post-Traumatic Pain</p> <p>alternative dictionary used: MedDRA 23.1</p>	<p>1 / 14 (7.14%)</p> <p>1</p> <p>1 / 14 (7.14%)</p> <p>1</p> <p>2 / 14 (14.29%)</p> <p>2</p>	<p>0 / 14 (0.00%)</p> <p>0</p> <p>0 / 14 (0.00%)</p> <p>0</p> <p>0 / 14 (0.00%)</p> <p>0</p>	<p>0 / 28 (0.00%)</p> <p>0</p> <p>0 / 28 (0.00%)</p> <p>0</p> <p>0 / 28 (0.00%)</p> <p>0</p>

subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Skin Laceration			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	1	1	0
Spinal Compression Fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Stress Fracture			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Vaccination Complication			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Atrial Fibrillation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 14 (14.29%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	2	0	0
Palpitations			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Burning Sensation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Cognitive Disorder			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	3 / 14 (21.43%)	1 / 14 (7.14%)	1 / 28 (3.57%)
occurrences (all)	3	1	1
Decreased Vibratory Sense			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Dizziness			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	1	1	0
Headache			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 14 (14.29%)	1 / 14 (7.14%)	5 / 28 (17.86%)
occurrences (all)	7	1	6
Memory Impairment			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Syncope			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Increased Tendency To Bruise			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	3 / 14 (21.43%)	3 / 14 (21.43%)	5 / 28 (17.86%)
occurrences (all)	3	3	5
Neutropenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	2 / 14 (14.29%)	0 / 28 (0.00%)
occurrences (all)	0	2	0
Ear and labyrinth disorders			
Tinnitus			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	2 / 14 (14.29%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	2	0	0
Vertigo			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Amaurosis Fugax			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Cataract			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	2 / 14 (14.29%)	1 / 28 (3.57%)
occurrences (all)	0	4	1
Cataract Subcapsular			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis Allergic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Dry Eye			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Eye Irritation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Keratitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Refraction Disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Vision Blurred			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 14 (14.29%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	2	0	0
Vitreous Floaters			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal Pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1
Abdominal Pain Upper			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Constipation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Dental Caries			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	2 / 14 (14.29%)	3 / 14 (21.43%)	2 / 28 (7.14%)
occurrences (all)	2	3	4
Dysphagia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Inguinal Hernia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Large Intestine Polyp			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Nausea			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Vomiting			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	3 / 28 (10.71%)
occurrences (all)	0	0	3
Skin and subcutaneous tissue disorders			
Alopecia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	2 / 14 (14.29%)	2 / 28 (7.14%)
occurrences (all)	0	2	2
Ecchymosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Eczema			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Erythema			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Hirsutism			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 14 (14.29%)	1 / 14 (7.14%)	2 / 28 (7.14%)
occurrences (all)	2	1	2
Hyperhidrosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	1 / 14 (7.14%)	1 / 28 (3.57%)
occurrences (all)	1	1	1
Hypertrichosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	0	0	0
Miliaria			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Night Sweats			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Photosensitivity Reaction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Skin Atrophy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0

<p>Skin Discharge</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 14 (7.14%)</p> <p>1</p>	<p>0 / 14 (0.00%)</p> <p>0</p>	<p>0 / 28 (0.00%)</p> <p>0</p>
<p>Skin Exfoliation</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 14 (0.00%)</p> <p>0</p>	<p>1 / 14 (7.14%)</p> <p>1</p>	<p>0 / 28 (0.00%)</p> <p>0</p>
<p>Skin Fragility</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 14 (0.00%)</p> <p>0</p>	<p>1 / 14 (7.14%)</p> <p>1</p>	<p>0 / 28 (0.00%)</p> <p>0</p>
<p>Skin Striae</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 14 (7.14%)</p> <p>1</p>	<p>2 / 14 (14.29%)</p> <p>2</p>	<p>0 / 28 (0.00%)</p> <p>0</p>
<p>Skin Ulcer</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 14 (7.14%)</p> <p>1</p>	<p>0 / 14 (0.00%)</p> <p>0</p>	<p>1 / 28 (3.57%)</p> <p>1</p>
<p>Urticaria</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 14 (7.14%)</p> <p>1</p>	<p>0 / 14 (0.00%)</p> <p>0</p>	<p>0 / 28 (0.00%)</p> <p>0</p>
<p>Endocrine disorders</p> <p>Adrenal Insufficiency</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Goitre</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 14 (7.14%)</p> <p>1</p> <p>1 / 14 (7.14%)</p> <p>1</p>	<p>0 / 14 (0.00%)</p> <p>0</p> <p>0 / 14 (0.00%)</p> <p>0</p>	<p>0 / 28 (0.00%)</p> <p>0</p> <p>0 / 28 (0.00%)</p> <p>0</p>
<p>Musculoskeletal and connective tissue disorders</p>			

Arthralgia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	4 / 14 (28.57%)	2 / 28 (7.14%)
occurrences (all)	0	4	2
Arthropathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Back Pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	1	1	0
Bursitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	2 / 14 (14.29%)	1 / 28 (3.57%)
occurrences (all)	1	3	1
Chondrocalcinosis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Intervertebral Disc Protrusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	1 / 28 (3.57%)
occurrences (all)	0	1	1
Muscle Spasms			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	1 / 28 (3.57%)
occurrences (all)	0	1	1
Musculoskeletal Chest Pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Myopathy			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Osteoarthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	2 / 28 (7.14%)
occurrences (all)	0	2	2
Osteopenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Pain In Extremity			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Pain In Jaw			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Rotator Cuff Syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	1 / 28 (3.57%)
occurrences (all)	1	0	1
Spinal Osteoarthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Cellulitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Cystitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	3
Gastroenteritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Herpes Simplex			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	4
Herpes Zoster			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	1 / 28 (3.57%)
occurrences (all)	0	1	1
Influenza			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	1 / 28 (3.57%)
occurrences (all)	0	1	1
Localised Infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0
Oral Candidiasis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Oral Herpes			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	1 / 28 (3.57%)
occurrences (all)	0	0	1

Respiratory Tract Infection alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1	0 / 28 (0.00%) 0
Rhinitis alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1	1 / 28 (3.57%) 1
Sinusitis alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1	0 / 28 (0.00%) 0
Tooth Infection alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0	0 / 28 (0.00%) 0
Urinary Tract Infection Bacterial alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1	0 / 28 (0.00%) 0
Viral Upper Respiratory Tract Infection alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0	0 / 28 (0.00%) 0
Metabolism and nutrition disorders Decreased Appetite alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	1 / 14 (7.14%) 1	0 / 14 (0.00%) 0	0 / 28 (0.00%) 0
Glucose Tolerance Impaired alternative dictionary used: MedDRA 23.1 subjects affected / exposed occurrences (all)	0 / 14 (0.00%) 0	1 / 14 (7.14%) 1	0 / 28 (0.00%) 0
Hypercholesterolaemia alternative dictionary used:			

MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 14 (0.00%)	2 / 28 (7.14%)
occurrences (all)	0	0	2
Hyperlipidaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 14 (0.00%)	1 / 14 (7.14%)	0 / 28 (0.00%)
occurrences (all)	0	1	0
Steroid Diabetes			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 14 (0.00%)	0 / 28 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Sarilumab 200mg q2w+26 week taper		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 27 (74.07%)		
Vascular disorders			
Hypertension			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
Hypertensive Emergency			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Peripheral Arterial Occlusive Disease			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Phlebitis			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Fatigue			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Injection Site Erythema			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Injection Site Pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Injection Site Pruritus			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Injection Site Rash			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Injection Site Reaction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Injection Site Swelling			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Malaise			
alternative dictionary used: MedDRA 23.1			

<p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Oedema Peripheral</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>2 / 27 (7.41%)</p> <p>occurrences (all)</p> <p>2</p> <p>Vessel Puncture Site Phlebitis</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Reproductive system and breast disorders</p> <p>Uterine Polyp</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Allergic Cough</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Cough</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>2 / 27 (7.41%)</p> <p>occurrences (all)</p> <p>2</p> <p>Dyspnoea</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Dyspnoea Exertional</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Emphysema</p> <p>alternative dictionary used: MedDRA 23.1</p>			

<p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Oropharyngeal Pain</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Sleep Apnoea Syndrome</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Psychiatric disorders</p> <p>Depressed Mood</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Depression</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p> <p>Insomnia</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>2 / 27 (7.41%)</p> <p>occurrences (all)</p> <p>2</p> <p>Mania</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>2</p>			
<p>Investigations</p> <p>Creatinine Renal Clearance Decreased</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>International Normalised Ratio Increased</p> <p>alternative dictionary used: MedDRA 23.1</p>			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Weight Increased</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>2 / 27 (7.41%)</p> <p>2</p>		
<p>Injury, poisoning and procedural complications</p> <p>Arthropod Bite</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Contusion</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Fall</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Post-Traumatic Pain</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Skin Laceration</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Spinal Compression Fracture</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Stress Fracture</p> <p>alternative dictionary used: MedDRA 23.1</p>	<p>0 / 27 (0.00%)</p> <p>0</p> <p>1 / 27 (3.70%)</p> <p>2</p> <p>4 / 27 (14.81%)</p> <p>4</p> <p>2 / 27 (7.41%)</p> <p>2</p> <p>1 / 27 (3.70%)</p> <p>2</p> <p>0 / 27 (0.00%)</p> <p>0</p>		

<p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Vaccination Complication</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Cardiac disorders</p> <p>Atrial Fibrillation</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p> <p>Palpitations</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Nervous system disorders</p> <p>Burning Sensation</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Cognitive Disorder</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p> <p>Decreased Vibratory Sense</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Dizziness</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Headache</p> <p>alternative dictionary used: MedDRA 23.1</p>			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>4 / 27 (14.81%)</p> <p>5</p>			
<p>Memory Impairment</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 27 (0.00%)</p> <p>0</p>			
<p>Syncope</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 27 (0.00%)</p> <p>0</p>			
<p>Blood and lymphatic system disorders</p> <p>Increased Tendency To Bruise</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>3 / 27 (11.11%)</p> <p>4</p> <p>Neutropenia</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 27 (0.00%)</p> <p>0</p>			
<p>Ear and labyrinth disorders</p> <p>Tinnitus</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>Vertigo</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>1 / 27 (3.70%)</p> <p>1</p>			
<p>Eye disorders</p> <p>Amaurosis Fugax</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>Cataract</p> <p>alternative dictionary used: MedDRA 23.1</p>			

subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Cataract Subcapsular			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Conjunctivitis Allergic			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Dry Eye			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Eye Irritation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Keratitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Refraction Disorder			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Vision Blurred			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Vitreous Floaters			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

Gastrointestinal disorders			
Abdominal Pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	3		
Abdominal Pain Upper			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Constipation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Dental Caries			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Diarrhoea			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	4		
Dysphagia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Inguinal Hernia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Large Intestine Polyp			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Nausea			
alternative dictionary used: MedDRA 23.1			

<p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Vomiting</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Skin and subcutaneous tissue disorders</p> <p>Alopecia</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Ecchymosis</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Eczema</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>2 / 27 (7.41%)</p> <p>occurrences (all)</p> <p>2</p> <p>Erythema</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p> <p>Hirsutism</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Hyperhidrosis</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Hypertrichosis</p> <p>alternative dictionary used: MedDRA 23.1</p>			

subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
Miliaria			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Night Sweats			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Photosensitivity Reaction			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Skin Atrophy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Skin Discharge			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Skin Exfoliation			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Skin Fragility			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Skin Striae			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		

<p>Skin Ulcer</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Urticaria</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Endocrine disorders</p> <p>Adrenal Insufficiency</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Goitre</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p>			
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>2 / 27 (7.41%)</p> <p>occurrences (all)</p> <p>3</p> <p>Arthropathy</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>0 / 27 (0.00%)</p> <p>occurrences (all)</p> <p>0</p> <p>Back Pain</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p> <p>Bursitis</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>1 / 27 (3.70%)</p> <p>occurrences (all)</p> <p>1</p> <p>Chondrocalcinosis</p>			

alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Intervertebral Disc Protrusion			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Muscle Spasms			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Musculoskeletal Chest Pain			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Myopathy			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Osteoarthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Osteopenia			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Pain In Extremity			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Pain In Jaw			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Rotator Cuff Syndrome			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Spinal Osteoarthritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Cellulitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Cystitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Gastroenteritis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Herpes Simplex			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Herpes Zoster			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Influenza			
alternative dictionary used: MedDRA 23.1			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Localised Infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Oral Candidiasis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Oral Herpes			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
Respiratory Tract Infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Rhinitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Sinusitis			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Tooth Infection			
alternative dictionary used: MedDRA 23.1			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

<p>Urinary Tract Infection Bacterial</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p>		
<p>Viral Upper Respiratory Tract Infection</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 27 (0.00%)</p> <p>0</p>		
<p>Metabolism and nutrition disorders</p> <p>Decreased Appetite</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Glucose Tolerance Impaired</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hypercholesterolaemia</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hyperlipidaemia</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hypokalaemia</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Steroid Diabetes</p> <p>alternative dictionary used: MedDRA 23.1</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>1 / 27 (3.70%)</p> <p>1</p> <p>0 / 27 (0.00%)</p> <p>0</p> <p>0 / 27 (0.00%)</p> <p>0</p>		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
12 September 2018	<p>The following amendment changes were done:</p> <ul style="list-style-type: none">- The assumed treatment effects used for the power calculations were added for clarity.- Sub-section of benefit and risk assessment was created to address a specific request from the European Regulatory Authorities and to align it with the current protocol template of the Sponsor.- Additional detail was added to method of assigning subjects to treatment group section to provide clarity on the randomisation procedure, particularly pertaining to the blocked randomisation and stratification process employed in the study.- Based on the results from the GiACTA study, the non-inferiority test was deemed as unnecessary and thus removed from the protocol.- Details on the hierarchical testing sequence for the secondary endpoints were added for clarification to address a specific request from the European Regulatory Authorities.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
19 March 2020	Study was prematurely discontinued due to protracted enrolment exacerbated by Covid-19 pandemic situation, screening/recruitment were suspended 19-Mar-2020, discontinued 21-Jul-2020.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Study was prematurely discontinued due to protracted enrolment exacerbated by Covid-19 pandemic situation and not due to any safety issues from administration of sarilumab.

Notes: